Loading…
Protagonist Therapeutics, Inc. is projected to rise to $173.73 by 2027, a +32% move from its current price of $132.01. PTGX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $128.73 | $132.10 | $135.56 | +0.07% |
| Jul 13 | $127.44 | $132.19 | $137.11 | +0.14% |
| Jul 14 | $126.49 | $132.28 | $138.33 | +0.20% |
| Jul 15 | $125.70 | $132.37 | $139.39 | +0.27% |
| Jul 16 | $125.02 | $132.46 | $140.34 | +0.34% |
| Jul 17 | $124.42 | $132.55 | $141.21 | +0.41% |
| Jul 18 | $123.87 | $132.64 | $142.02 | +0.47% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $123.87 | $132.64 | $142.02 | +0.47% |
| Week 2 | $120.98 | $133.26 | $146.79 | +0.95% |
| Week 3 | $118.94 | $133.90 | $150.73 | +1.43% |
| Week 4 | $117.34 | $134.53 | $154.24 | +1.91% |
| Week 5 | $116.00 | $135.17 | $157.49 | +2.39% |
| Week 6 | $114.87 | $135.81 | $160.57 | +2.88% |
| Week 7 | $113.87 | $136.45 | $163.51 | +3.36% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera.
The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Protagonist Therapeutics, Inc. (PTGX) is a Healthcare company with a current price of $140.85 per share and a market capitalization of $9.06B. It ranks 984 by market cap among listed companies.
The stock’s near-term outlook shows an even risk profile in 2026, with a 2026 avg price of $140.85 but a range from $79.73 to $196.66 and a neutral sentiment, before stronger upside emerges in subsequent years.
A major floor 43.8% below — a decisive break under it would weaken the trend.
The nearest floor, 29.4% below — buyers have tended to step in here.
The nearest ceiling, 6.7% above — a clean break opens room to run.
A major ceiling 28.4% above — clearing it would confirm fresh momentum.
Key PTGX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PTGX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $136.30 | Sell | $134.25 | Sell |
| MA 10 | $130.44 | Buy | $130.76 | Buy |
| MA 20 | $122.50 | Buy | $123.98 | Buy |
| MA 50 | $109.17 | Buy | $113.39 | Buy |
| MA 100 | $103.30 | Buy | $104.81 | Buy |
| MA 200 | $92.24 | Buy | $92.88 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.69 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 73.43 | Neutral |
| Williams %R (14) | -36.52 | Info |
| MACD (12,26,9) | 1.10 | Buy |
| ROC (12) | 10.47 | Buy |
| Bollinger %B (20,2) | 0.72 | Neutral |
| Stochastic %K (14) | 63.48 | Neutral |
| TRIX (15) | 0.96 | Buy |
| Awesome (5,34) | 23.15 | Buy |
| Ultimate (7,14,28) | 68.56 | Neutral |
| Momentum (10) | 8.79 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 140.42 | Sell |
| ADX (14) | 36.96 | Buy |
| ATR (14) | 2.86 | Info |
Technically, the 30-day picture is bullish with RSI(14) at 80, indicating elevated momentum. The 50-day simple moving average stands at $106.99 and the 200-day simple moving average at $91.14, creating a supportive base near $93.23 and a resistance at $140.85. The stock has traded within a 30-day range of $118.80 to $166.99, reflecting a broad exploratory window for near-term moves.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $79.73 | $132.01 | $184.05 | 0% | Neutral | |
| $138.99 | $173.73 | $229.32 | +32% | Bullish | |
| $160.34 | $205.75 | $281.31 | +56% | Bullish | |
| $193.06 | $253.17 | $355.84 | +92% | Bullish | |
| $257.04 | $343.59 | $494.29 | +160% | Bullish | |
| $292.07 | $397.27 | $583.25 | +201% | Bullish | |
| $321.87 | $444.97 | $665.30 | +237% | Bullish | |
| $375.59 | $527.17 | $801.35 | +299% | Bullish | |
| $380.81 | $542.27 | $836.94 | +311% | Bullish | |
| $414.77 | $598.81 | $937.37 | +354% | Bullish | |
| $690.23 | $1,060.63 | $1,761.80 | +703% | Bullish | |
| $1,563.77 | $2,673.33 | $4,842.86 | +19.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $79.73 | $132.01 | $156.18 | +0.00% |
| August 2026 | $113.46 | $133.75 | $161.78 | +1.32% |
| September 2026 | $118.32 | $140.39 | $171.60 | +4.97% |
| October 2026 | $119.72 | $142.86 | $176.18 | +1.76% |
| November 2026 | $118.95 | $142.62 | $177.19 | -0.17% |
| December 2026 | $122.17 | $147.14 | $184.05 | +3.17% |
Click any year to see its month-by-month PTGX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The PTGX price prediction for 2026 points to an average of $132.01 (low $79.73, high $184.05) — a potential gain of 0% on today's $132.01. Price action looks broadly range-bound.
In 2027, PTGX is projected to trade between $138.99 and $229.32, averaging $173.73 — a potential gain of +32% from today's $132.01. That is up +32% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Protagonist Therapeutics, Inc.'s 2028 outlook centres on $205.75, within a $160.34 to $281.31 range. That is up +18% on the projected 2027 average. That marks a +56% change versus current levels. Momentum favours further upside here.
By 2029, PTGX could reach as high as $355.84, with a base case around $253.17 and support toward $193.06 — roughly +92% from $132.01. Buyers look set to stay in control over this stretch.
Expect PTGX to range from $257.04 to $494.29 through 2030. The $343.59 average target implies a +160% move from current prices. That is up +36% on the projected 2029 average. Momentum favours further upside here.
The PTGX price prediction for 2031 points to an average of $397.27 (low $292.07, high $583.25) — a potential gain of +201% on today's $132.01. Buyers look set to stay in control over this stretch.
In 2032, PTGX is projected to trade between $321.87 and $665.30, averaging $444.97 — a potential gain of +237% from today's $132.01. That is up +12% on the projected 2031 average. Momentum favours further upside here.
Protagonist Therapeutics, Inc.'s 2033 outlook centres on $527.17, within a $375.59 to $801.35 range. That is up +18% on the projected 2032 average. That marks a +299% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, PTGX could reach as high as $836.94, with a base case around $542.27 and support toward $380.81 — roughly +311% from $132.01. Momentum favours further upside here.
Expect PTGX to range from $414.77 to $937.37 through 2035. The $598.81 average target implies a +354% move from current prices. That is up +10% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The PTGX price prediction for 2040 points to an average of $1,060.63 (low $690.23, high $1,761.80) — a potential gain of +703% on today's $132.01. Momentum favours further upside here.
In 2050, PTGX is projected to trade between $1,563.77 and $4,842.86, averaging $2,673.33 — a potential gain of +19.3x from today's $132.01. That is up +152% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in PTGX today (≈ 7.575184 PTGX) could be worth
$20,251
+$19,251 (+1925%) by 2050 · US Dollar
Based on the average projected PTGX price of $2,673.33 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PTGXwould be worth at today's price.
$1,000 invested in PTGX on Jul 10, 2025 (≈ 18.93043 PTGX) would be worth
$2,499.01
+$1,499.01 (+149.9%) today · 2.50× · US Dollar
Based on a PTGX entry price of $52.83 vs. today's $132.01.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $131.62 | $1,002.96 | +0.3% |
| 1 month ago | $105.77 | $1,248.09 | +24.8% |
| 3 months ago | $98.82 | $1,335.86 | +33.6% |
| 6 months ago | $80.25 | $1,644.98 | +64.5% |
| 1 year ago | $52.83 | $2,499.01 | +149.9% |
| All time (5.0y) ago | $46.32 | $2,849.96 | +185.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PTGX forecast.
Our base-case forecast reaches $260.00 around 2030.
Implied market cap at $260.00: $16.72B
The multi-year forecast shows a clear upside path with rising averages and high-end targets. For 2030 the model gives an average price of $362.62 and a max of $521.70 with a 157.4% ROI and bullish sentiment, illustrating substantial longer-term upside. Earlier years like 2027–2029 show positive momentum, culminating in a 2040 average of $1,077.01 with a 664.6% ROI and a 2050 average of $2,735.49 with a 1,842.1% ROI, all tagged as bullish.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $362.62, a minimum of $271.27, and a maximum of $521.70 with an ROI of 157.4% and a bullish sentiment.
Forecasts show bullish sentiment from 2027 onward, with substantial upside by 2030 and later years; the near term (2026) is neutral with an average of $140.85. These are estimates, not guarantees.
Yes. The 2040 forecast lists an average of $1,077.01 and a maximum of $1,788.80, with a bullish outlook and a 664.6% ROI.
The 2050 forecast lists an average of $2,735.49 and a maximum of $4,954.57, with a bullish sentiment. The maximum is below $5,000, so a 5,000-level is not projected.
The current price is $140.85 and the market capitalization is $9.06B.
Protagonist Therapeutics, Inc. Community Discussion
0Share your Protagonist Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.